Have a feature idea you'd love to see implemented?
Let us know!
CYTK Cytokinetics Inc
Price (delayed)
$47.67
Market cap
$5.63B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.38
Enterprise value
$6.37B
Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by
Highlights
The EPS has grown by 3.1% YoY
CYTK's equity has dropped by 113% since the previous quarter but it has surged by 97% year-on-year
Cytokinetics's gross profit has plunged by 59% YoY but it has increased by 2.7% from the previous quarter
The net income is down by 9% year-on-year and by 6% since the previous quarter
The debt has increased by 5% YoY
Key stats
What are the main financial stats of CYTK
Market
Valuations
Earnings
Shares outstanding
118.01M
Market cap
$5.63B
Enterprise value
$6.37B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1,742.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,978.4
Revenue
$3.22M
EBIT
-$540.48M
EBITDA
-$526.99M
Free cash flow
-$407.05M
Per share
Balance sheet
Liquidity
EPS
-$5.38
Free cash flow per share
-$3.46
Book value per share
-$0.12
Revenue per share
$0.03
TBVPS
$12.2
Total assets
$1.44B
Total liabilities
$1.45B
Debt
$789.63M
Equity
-$13.91M
Working capital
$908.79M
Debt to equity
-56.76
Current ratio
9.28
Quick ratio
9.22
Net debt/EBITDA
-1.41
Margins
Efficiency
Dividend
EBITDA margin
-16,371.3%
Gross margin
100%
Net margin
-17,906.2%
Operating margin
-16,297.8%
Return on assets
-50.2%
Return on equity
N/A
Return on invested capital
-31.8%
Return on capital employed
-40.8%
Return on sales
-16,790.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CYTK stock price
How has the Cytokinetics stock price performed over time
Intraday
-4.39%
1 week
-12.85%
1 month
-11.41%
1 year
50.19%
YTD
-42.9%
QTD
-9.72%
Financial performance
How have Cytokinetics's revenue and profit performed over time
Revenue
$3.22M
Gross profit
$3.22M
Operating income
-$524.63M
Net income
-$576.4M
Gross margin
100%
Net margin
-17,906.2%
The net margin has plunged by 166% YoY and by 2.9% from the previous quarter
Cytokinetics's operating margin has plunged by 157% YoY
Cytokinetics's gross profit has plunged by 59% YoY but it has increased by 2.7% from the previous quarter
The revenue has dropped by 59% year-on-year but it has increased by 2.7% since the previous quarter
Growth
What is Cytokinetics's growth rate over time
Valuation
What is Cytokinetics stock price valuation
P/E
N/A
P/B
N/A
P/S
1,742.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,978.4
The EPS has grown by 3.1% YoY
CYTK's equity has dropped by 113% since the previous quarter but it has surged by 97% year-on-year
The revenue has dropped by 59% year-on-year but it has increased by 2.7% since the previous quarter
CYTK's P/S is 2.6% above its last 4 quarters average of 1698.4
Efficiency
How efficient is Cytokinetics business performance
The ROS has plunged by 163% YoY and by 2.9% from the previous quarter
The company's return on assets rose by 18% YoY and by 10% QoQ
CYTK's return on invested capital is up by 8% year-on-year and by 6% since the previous quarter
Dividends
What is CYTK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CYTK.
Financial health
How did Cytokinetics financials performed over time
The total assets has surged by 94% year-on-year but it has declined by 6% since the previous quarter
Cytokinetics's quick ratio has increased by 32% YoY but it has decreased by 10% from the previous quarter
CYTK's equity has dropped by 113% since the previous quarter but it has surged by 97% year-on-year
The debt has increased by 5% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.